



BLA 125164/S-062

SUPPLEMENT APPROVAL

Hoffmann-La Roche, Inc.
c/o Genentech, Inc.
Attention: Elizabeth Wishart
Regulatory Agent
1 DNA Way, MS 241B
South San Francisco, CA 94080-4990

Dear Ms. Wishart:

Please refer to your Supplemental Biologics License Application (sBLA), dated July 30, 2014, received July 30, 2014, submitted under section 351(a) of the Public Health Service Act for Mircera[®] (methoxy polyethylene glycol-epoetin beta).

We acknowledge receipt of your amendments dated July 30, August 14, and September 15 and 25, 2014. The July 30, 2014 submission constituted a complete response to our July 16, 2014 action letter.

This Prior Approval supplemental biologics application proposes an update to Mircera United States Prescribing Information (USPI), Medication Guide, and Information for Use for consistency with contemporary usage of similar products and to reflect current manufacturing dosage forms.

APPROVAL & LABELING

We have completed our review of this supplemental application, as amended. It is approved, effective on the date of this letter, for use as recommended in the enclosed, agreed-upon labeling text.

CONTENT OF LABELING

As soon as possible, but no later than 14 days from the date of this letter, submit, via the FDA automated drug registration and listing system (eLIST), the content of labeling [21 CFR 601.14(b)] in structured product labeling (SPL) format, as described at <http://www.fda.gov/ForIndustry/DataStandards/StructuredProductLabeling/default.htm>, that is identical to the enclosed labeling (text for the package insert, Medication Guide, Instructions for Use) and include the labeling changes proposed in any pending "Changes Being Effected" (CBE) supplements. Information on submitting SPL files using eLIST may be found in the

guidance for industry titled “SPL Standard for Content of Labeling Technical Qs and As” at <http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM072392.pdf>.

The SPL will be accessible via publicly available labeling repositories.

Also within 14 days, amend all pending supplemental applications that include labeling changes for this BLA, including pending “Changes Being Effected” (CBE) supplements, for which FDA has not yet issued an action letter, with the content of labeling [21 CFR 601.12(f)] in MS Word format that includes the changes approved in this supplemental application.

REQUIRED PEDIATRIC ASSESSMENTS

Under the Pediatric Research Equity Act (PREA) (21 U.S.C. 355c), all applications for new active ingredients, new indications, new dosage forms, new dosing regimens, or new routes of administration are required to contain an assessment of the safety and effectiveness of the product for the claimed indication(s) in pediatric patients unless this requirement is waived, deferred, or inapplicable. Because none of these criteria apply to your application, you are exempt from this requirement.

POSTMARKETING COMMITMENTS SUBJECT TO REPORTING REQUIREMENTS UNDER SECTION 506B

We remind you of your postmarketing commitment:

PMC 2796-1: Conduct an ongoing study of Mircera usage in the U.S. to assess usage in all patient populations in which ESA therapy is indicated, to assess extent of Mircera use in accordance with the approved indications for Mircera. Submit a protocol that will allow assessment of marketed use broadly in the U.S., including documentation of the adequacy of the survey process utilized. Upon study completion, submit a full report and identify whether any further steps should be considered to reinforce use only in the renal anemia setting.

The timetable you submitted on September 25, 2014 states that you will conduct this study according to the following schedule:

| | |
|----------------------------|---------|
| Draft Protocol Submission: | 12/2014 |
| Final Protocol Submission: | 03/2015 |
| Interim Report Submission: | 09/2015 |
| Interim Report Submission: | 09/2016 |
| Study Completion: | 09/2017 |
| Final Report Submission: | 03/2018 |

Submit clinical protocols to your IND (b) (4) for this product. Submit nonclinical and chemistry, manufacturing, and controls protocols and all postmarketing final reports to this BLA. In addition, under 21 CFR 601.70 you should include a status summary of each commitment in your annual progress report of postmarketing studies to this BLA. The status summary should include expected summary completion and final report submission dates, any changes in plans since the last annual report, and, for clinical studies/trials, number of patients entered into each study/trial. All submissions, including supplements, relating to these postmarketing commitments should be prominently labeled “**Postmarketing Commitment Protocol,**” “**Postmarketing Commitment Final Report,**” or “**Postmarketing Commitment Correspondence.**”

PROMOTIONAL MATERIALS

You may request advisory comments on proposed introductory advertising and promotional labeling. To do so, submit, in triplicate, a cover letter requesting advisory comments, the proposed materials in draft or mock-up form with annotated references, and the package insert(s) to:

Food and Drug Administration
Center for Drug Evaluation and Research
Office of Prescription Drug Promotion
5901-B Ammendale Road
Beltsville, MD 20705-1266

As required under 21 CFR 601.12(f)(4), you must submit final promotional materials, and the package insert(s), at the time of initial dissemination or publication, accompanied by a Form FDA 2253. Form FDA 2253 is available at

<http://www.fda.gov/downloads/AboutFDA/ReportsManualsForms/Forms/UCM083570.pdf>.

Information and Instructions for completing the form can be found at

<http://www.fda.gov/downloads/AboutFDA/ReportsManualsForms/Forms/UCM375154.pdf>. For more information about submission of promotional materials to the Office of Prescription Drug Promotion (OPDP), see <http://www.fda.gov/AboutFDA/CentersOffices/CDER/ucm090142.htm>.

All promotional materials for your drug product that include representations about your drug product must be promptly revised to make it consistent with the labeling changes approved in this supplement, including any new safety information [21 CFR 601.12(a)(4)]. The revisions to your promotional materials should include prominent disclosure of the important new safety information that appears in the revised package labeling. Within 7 days of receipt of this letter, submit your statement of intent to comply with 21 CFR 601.12(a)(4) to the address above or by fax to 301-847-8444.

REPORTING REQUIREMENTS

We remind you that you must comply with reporting requirements for an approved BLA (in 21 CFR 600.80 and in 21 CFR 600.81).

If you have any questions, call Amy Chi, Regulatory Project Manager at (240) 402-0992.

Sincerely,

{See appended electronic signature page}

Robert C. Kane, MD
Deputy Director for Safety
Division of Hematology Products
Office of Hematology and Oncology Products
Center for Drug Evaluation and Research

ENCLOSURES:

Content of Labeling
Medication Guide
Information for Use

This is a representation of an electronic record that was signed electronically and this page is the manifestation of the electronic signature.

/s/

ROBERT C KANE
10/01/2014